Clinical trials
Pembrolizumab clinical trials
Below are recruiting pembrolizumab clinical trials, each written for real people, not researchers. We’re tracking 613 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05753722RecruitingPhase 1
First trial for PRTH-101 alone or with pembrolizumab
This early study tests PRTH-101, given by itself or with pembrolizumab, in people with advanced cancers that have spread or cannot be removed by surgery. The goal is to see if it is safe and how it affects the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05766371RecruitingPhase 2
Pembrolizumab plus PSMA-targeted therapy for advanced prostate cancer
This Phase 2 trial tests whether adding pembrolizumab to a PSMA-targeted drug can better treat metastatic prostate cancer that has progressed despite hormone-blocking treatments. It may help some people by attacking PSMA-positive cancer spots seen on a special PET scan.
San Francisco, CaliforniaAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05920798RecruitingPhase 1/Phase 2
Vaccine treatment plus pembrolizumab for recurrent ovarian cancer
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Scottsdale, ArizonaAges 18 years+ - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05961761RecruitingPhase 2
Testing propranolol plus pembrolizumab for advanced sarcoma
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
AarhusAges 18 years+ - NCT05967182RecruitingPhase 2
Pembrolizumab plus chemo before or around liver surgery
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
Houston, TexasAges 18 years+ - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+ - NCT05977907RecruitingPhase 2
Immunotherapy before surgery for head and neck cancer
This Phase 2 trial tests pembrolizumab and an investigational drug (IO102-103) given before surgery for certain non-bulky head and neck squamous cell cancers. The goal is to shrink the cancer and improve chances of cure by treating it before the operation.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06001658RecruitingPhase 2
Chemo plus immunotherapy before and after surgery for bile duct cancer
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
Baltimore, MarylandAges 18 years+ - NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06016920RecruitingPhase 1/Phase 2
HPV16 vaccine plus Keytruda for oropharyngeal cancer
This trial tests a new vaccine (VB10.16) combined with the immunotherapy Keytruda (pembrolizumab) for people with HPV16-positive oropharyngeal cancer that has spread or come back. The goal is to see if the combination helps shrink tumors or slow cancer growth.
OlomoucAges 18 years+ - NCT06066333RecruitingPhase 2
Radiation and immunotherapy for adrenal cancer with liver spread
This trial tests whether adding a type of immunotherapy (pembrolizumab) to targeted radiation can help people with adrenal cancer that has spread to the liver. It aims to shrink tumors and slow the cancer's growth.
Basking Ridge, New JerseyAges 18 years+ - NCT06078384RecruitingPhase 2
Pembrolizumab and chemo for early-stage triple-negative breast cancer
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
AmiensAges 18 years+ - NCT06083844RecruitingPhase 2
Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
New York, New YorkAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Encinitas, CaliforniaAges 18 years+ - NCT06113809RecruitingPhase 1
Palbociclib and pembrolizumab for advanced sarcoma
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
Iowa City, IowaAges 12 years+ - NCT06123338RecruitingPhase 2
Pembrolizumab plus chemo and trastuzumab for HER2+ stomach cancer
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Boston, MassachusettsAges 18 years+
Hear when a new Pembrolizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pembrolizumab?
- Yes. Clin2 currently lists 613 recruiting pembrolizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pembrolizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pembrolizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.